Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
October 22, 2019 at 03:55 am
Share
Nanjing Hicin Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 684.595 million compared to CNY 525.624 million a year ago. Operating income was CNY 90.492 million compared to CNY 72.415 million a year ago. Net income was CNY 77.461 million compared to CNY 62.296 million a year ago. Basic earnings per share from continuing operations was CNY 0.6455 compared to CNY 0.5191 a year ago.
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
NANJING HICIN PHARMACEUTICAL CO., LTD. 
